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Edited by Robert BaroukiAbstract To assess glucagon receptor compartmentalization
and signal transduction in liver parenchyma, we have studied
the functional relationship between glucagon receptor endocyto-
sis, phosphorylation and coupling to the adenylate cyclase sys-
tem. Following administration of a saturating dose of glucagon
to rats, a rapid internalization of glucagon receptor was observed
coincident with its serine phosphorylation both at the plasma
membrane and within endosomes. Co-incident with glucagon
receptor endocytosis, a massive internalization of both the 45-
and 47-kDa Gsa proteins was also observed. In contrast, no
change in the subcellular distribution of adenylate cyclase or b-
arrestin 1 and 2 was observed. In response to des-His1-[Glu9]glu-
cagon amide, a glucagon receptor antagonist, the extent and rate
of glucagon receptor endocytosis and Gsa shift were markedly
reduced compared with wild-type glucagon. However, while the
glucagon analog exhibited a wild-type aﬃnity for endosomal
acidic glucagonase activity and was processed at low pH with
similar kinetics and rates, its proteolysis at neutral pH was 3-
fold lower. In response to tetraiodoglucagon, a glucagon receptor
agonist of enhanced biological potency, glucagon receptor endo-
cytosis and Gsa shift were of higher magnitude and of longer
duration, and a marked and prolonged activation of adenylate
cyclase both at the plasma membrane and in endosomes was ob-
served. The subsequent post-endosomal fate of internalized Gsa
was evaluated in a cell-free rat liver endosome–lysosome fusion
system following glucagon injection. A sustained endo-lysosomal
transfer of the two 45- and 47-kDa Gsa isoforms was observed.
Therefore, these results reveal that within hepatic target cells
and consequent to glucagon-mediated internalization of the ser-
ine-phosphorylated glucagon receptor and the Gsa protein, ex-
tended signal transduction may occur in vivo at the locus of
the endo-lysosomal apparatus.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glucagon is a 29 amino acid peptide hormone secreted by
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doi:10.1016/j.febslet.2006.09.021tant role in the regulation of blood glucose homeostasis by
stimulating glycogenolysis and gluconeogenesis [1]. The bio-
logical actions of glucagon are mediated by glucagon binding
to a membrane spanning receptor that activates adenylate cy-
clase via the heterotrimeric Gs protein, leading to a subsequent
increase in intracellular cAMP levels. In addition, the glucagon
receptor couples to an intracellular Ca2+-mediated pathway.
The glucagon receptor is a member of the family B of the G-
protein-coupled receptor (GPCR) superfamily [2]. Other clo-
sely related members of the family include the receptors for
glucagon-like peptide (GLP) 1 and 2, and glucose-dependent
insulinotropic peptide (GIP).
Glucagon receptor endocytosis has been demonstrated in
intact rat liver [3] and in CHO cells expressing the human
glucagon receptor [4], and has been hypothesized to be in-
volved in signal downregulation. Following glucagon recep-
tor occupation, the ligand-receptor complex accumulated in
a low density endosomal compartment with maximum accu-
mulation observed by 12–24 min [3,5,6]. Internalized gluca-
gon is rapidly proteolyzed within hepatic endosomes before
(at neutral pH) and after ATP-dependent endosomal acidiﬁ-
cation (at acidic pH) [7,8]. An undeﬁned endosomal serine
protease mediates glucagon proteolysis at neutral pH and
generates the bioactive miniglucagon peptide [8], whereas
membrane-bound forms of endosomal cathepsins B and D
mediate glucagon proteolysis after endosomal acidiﬁcation
[7].
Although the role of endosomal proteolysis of internalized
glucagon in signal downregulation has clearly been demon-
strated, the role of glucagon receptor endocytosis in regulat-
ing glucagon receptor signal transduction has been poorly
investigated [4]. Since the mechanism of endocytosis is dis-
tinct for diﬀerent GPCRs and may also depend on the cellu-
lar environment, it is important to examine glucagon
receptor regulation in vivo in the hepatic target tissue where
glucagon receptors are expressed at a high level. Accordingly,
we have used a preparative subcellular fractionation ap-
proach to address glucagon receptor compartmentalization
and signal transduction in vivo. Thus, we have studied (i)
the relationship between glucagon receptor endocytosis and
its phosphorylation state throughout the endocytic pathway,
(ii) the subcellular distribution and endocytic fate of
Gsa, adenylate cyclase and b-arrestin proteins upon
glucagon receptor endocytosis, and (iii) the ability of des-
His1-[Glu9]glucagon amide and tetraiodoglucagon to induce
the internalization of glucagon receptor and Gsa, to activateblished by Elsevier B.V. All rights reserved.
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lytic system.2. Materials and methods
2.1. Peptides, ligand radioiodination, antibodies, protein
determination, radioimmunoassay, enzyme assays and materials
Human glucagon and des-His1-[Glu9]glucagon were purchased from
Sigma. Tetraiodoglucagon ([I4]-glucagon) was prepared by the ICl
method as described previously [9]. Native glucagon was radioiodin-
ated by the lactoperoxidase method and puriﬁed by RP-HPLC to spe-
ciﬁc activities of 60–80 lCi/lg as described previously [5]. ST-18
glucagon receptor antibody is directed against a peptide corresponding
to residues 468–485 of the intracellular C-terminus [10]. Rabbit antise-
rum raised to a GST-fusion protein encoding the last 88 amino acids of
the carboxyl terminus of rat b-arrestin 1 (residues 331–418) was from
Dr. R. J. Lefkowitz (Duke University Medical Center, Durham, USA).
Rabbit polyclonal antibody directed against the Gsa proteins was from
NEN. Rabbit polyclonal antibody (C-17) directed against adenylate
cyclase V and VI was from Santa Cruz. Monoclonal antibodies raised
against phospho-serine or -threonine were purchased from Sigma.
Monoclonal antibody (clone 4G10) raised against phospho-tyrosine
was purchased from UBI. HRP conjugated goat anti-rabbit and
-mouse IgG were from Bio-Rad. The protein content of isolated
fractions was determined by the method of Lowry et al. [11]. Glucagon
and [I4]-glucagon associated with liver cell fractions were extracted
by acid as described previously [3] and their concentration was mea-
sured using a commercial radioimmunoassay kit (Linco). Galactosyl-
transferase was assayed as described by Beaufay et al. [12]. Acid
phosphatase was assayed as described by Trouet [13]. Adenylate cy-
clase activity was measured using [a-32P]ATP as substrate as described
previously [3]. Nitrocellulose membranes and Enhanced ChemiLumi-
nescence (ECL) detection kit were from Amersham. Protein G-Sephar-
ose was from Pharmacia. HPLC grade acetonitrile and triﬂuoroacetic
acid (TFA) were obtained from Baker Chemical Co. All other chemi-
cals were obtained from commercial sources and were of reagent
grade.2.2. Animals and injections
In vivo procedures were approved by the INSERM committee for
use and care of experimental animals. Male Sprague–Dawley rats,
body weight 180–200 g, were obtained from Charles River France
(St. Aubin Les Elbeufs, France) and were fasted for 18 h prior to sac-
riﬁce. Native glucagon, des-His1-[Glu9]glucagon (50 lg per 100 g body
weight) and [I4]-glucagon (25 lg per 100 g body weight) in 0.4 ml of
0.15 M NaCl were injected within 5 s into the penile vein under light
anaesthesia with ether.
2.3. Isolation of subcellular fractions from rat liver
Subcellular fractionation was performed using established proce-
dures. Following injection of native glucagon peptides, rats were sacri-
ﬁced and livers rapidly removed and minced in isotonic ice-cold
homogenization buﬀer as previously described [3,5,6].
Rat liver nuclear (N), large-granule (ML), microsomal (P) and
cytosolic (S) fractions were isolated by diﬀerential centrifugation as
previously described [5,8,14]. Plasma membrane (PM) was prepared
according to the method of Neville [15] as described by Authier
et al. [3,5,16]. The endosomal (EN) fraction was isolated by discontin-
uous sucrose gradient centrifugation and collected at the 0.25–1.0 M
sucrose interface [3,5–8]. When indicated two separate endosomal frac-
tions of intermediate (ENi) and high (ENh) density were isolated as de-
scribed previously [3,5]. The soluble endosomal extract (ENs) was
isolated from the EN fraction by freeze/thawing in 5 mM Na-phos-
phate, pH 7.4, and disrupted in the same hypotonic medium using a
small Dounce homogenizer (15 strokes with Type A pestle) followed
by centrifugation at 150000 · g for 60 min as previously described
[7,8,14,16,17].
2.4. In vitro endosome–lysosome transfer reaction
Cell-free endosome–lysosome transfer of in vivo internalized gluca-
gon receptor and Gsa proteins was studied as described previously
[18,19]. The postmitochondrial supernatant (referred to as LPS frac-tion) was incubated for 15 min at 4 or 37 C with 5 mM ATP, 1 mg/
ml creatine kinase and 20 mM phosphocreatine. After cooling to
4 C, incubation mixtures were subjected to centrifugation on linear
Nycodenz gradients as described previously [18,19]. The distribution
of Gsa protein and enzyme activities was determined and components
appearing at densities 1.065–1.11 and 1.11–1.145 g/ml were scored as
endosomal and lysosomal, respectively. The speciﬁcity of the endo-
lysosomal transfer of internalized proteins and that the density shift in-
volves a direct interaction between endosome and lysosome organelles
have been previously characterized [18,19].
2.5. Immunoblot analysis
Same amounts of cell fraction protein were analyzed on SDS/PAGE
followed by immunoblot analysis. For Nycodenz subfractions isolated
from endosome–lysosome transfer reaction, same volumes of fraction
were applied to each lane (see Fig. 1C). After SDS/PAGE, electropho-
resed samples were transferred onto nitrocellulose membranes for
60 min at 380 mA in transfer buﬀer containing 25 mM Tris base and
192 mM glycine. The membranes were blocked for 3 h with 5% skim
milk or 2% bovine serum albumin (for phospho-speciﬁc antibodies)
in 10 mM Tris–HCl, pH 7.5, 300 mM NaCl and 0.05% Tween 20.
The membranes were then incubated with primary antibody [poly-
clonal antibodies to glucagon receptor diluted 1:10000, b-arrestin 1
diluted 1:500, Gsa proteins diluted 1:500, adenylate cyclase V/VI
diluted 1:100, and monoclonal antibodies to phospho-tyrosine, -serine
and -threonine diluted 1:100] in the above buﬀer for 16 h at 4 C. The
blots were then washed three times with 0.5% skim milk or 0.2%
bovine serum albumin (for phospho-speciﬁc antibodies) in 10 mM
Tris–HCl, pH 7.5, 300 mM NaCl and 0.05% Tween 20 over a period
of 1 h at room temperature. The bound immunoglobulin was detected
using HRP-conjugated goat anti-rabbit IgG for the polyclonal anti-
bodies or HRP-conjugated goat anti-mouse IgG for the monoclonal
phospho-speciﬁc antibodies.
2.6. Immunoprecipitation
Plasma membrane and endosomal fractions (250 lg protein) were
lysed in HBS buﬀer (50 mM HEPES, pH 7.5, 200 mM NaCl) contain-
ing 1% Triton X-100, 0.5% deoxycholate, 1 mM PMSF, 0.5 mM 1,10-
phenanthroline, 0.1 lM E64 and 10 lg/ml pepstatin-A. Clariﬁcation of
the extracts was achieved by centrifugation for 1 h at 300000 · gav. Ly-
sates were precleared with protein G-Sepharose for 30 min at 4 C, and
incubated with polyclonal anti-glucagon receptor ST-18 (dilution
1:7500) for 2 h at 4 C. Protein G-Sepharose beads were then added,
and incubation at 4 C was continued with rotation for a further 2 h.
The suspension was then centrifuged at 15000 · gav for 1 min, the
supernatant discarded, and the beads washed three times with wash
buﬀer (50 mM HEPES, pH 7.5, 200 mM NaCl, 0.5% Triton X-100,
0.25% deoxycholate) and once with HBS. Immunoprecipitates were
analysed on SDS/PAGE gels followed by Western-blotting.2.7. In vitro proteolysis of glucagon peptides by hepatic endosomes
A soluble endosomal extract (ENs; 1 lg) was incubated for
varying lengths of time at 37 C with 30 lg native glucagon or des-
His1-[Glu9]glucagon in 90 ll of 55 mM citrate-phosphate buﬀer pH 4
or 7. To determine the integrity of the glucagon peptides, the samples
were acidiﬁed with acetic acid (15%) and immediately loaded onto a
RP-HPLC system as described previously [8]. Samples were chromato-
graphed using a mixture of 0.1% TFA in water (solvent A) and 0.1%
TFA in acetonitrile (solvent B) with a ﬂow rate of 1 ml/min. Elution
was carried out using two sequential linear gradients of 0–25% solvent
B (10 min) and 25–37% solvent B (40 min), followed by an isocratic
elution of 37% solvent B (10 min). Eluates were monitored on-line
for absorbance at 214 nm with a LC-166 spectrophotometer (Beckman
Coulter). Intact glucagon and des-His1-[Glu9]glucagon had an elution
time of 34 and 36 min, respectively.
For the in vitro degradation of [125I]-glucagon by ENs, the radiola-
beled glucagon (104 cpm) was incubated with 1 lg of soluble endo-
somal protein and various concentrations of unlabeled glucagon or
des-His1-[Glu9]glucagon in 50 mM citrate-phosphate buﬀer, pH 4,
for 7 min at 37 C. The amount of radiolabeled glucagon-degraded
was assayed by precipitation with 2 ml of ice-cold TCA (10%) for
2 h at 4 C. The samples were then centrifuged at 10000 · gav for
20 min at 4 C, and the supernatants and pellets evaluated for their
radioactive content using a Packard c-counter.
aFig. 1. Glucagon-mediated internalization of serine-phosphorylated glucagon receptor and Gsa in hepatic endosomes. (A) Plasma membrane (PM)
and endosomal fractions (EN) were isolated at the indicated times after the in vivo administration of native glucagon and evaluated by Western-
blotting for their content of glucagon receptor (anti-GR), Gsa (anti-Gsa) and adenylate cyclase (anti- AC). Fifty lg of protein was applied to each
lane. Molecular mass markers are indicated to the left of the upper blot. Arrows on the right indicate the mobility of immunodetected glucagon
receptor (62-kDa), Gsa (47- and 45-kDa) and adenylate cyclase (170-kDa). (B) PM and EN fractions (250 lg protein) were lysed and glucagon
receptor was immunoprecipitated with anti-glucagon receptor ST-18 (anti-GR), and the resultant immunoprecipitates were analyzed by Western-
blotting using the polyclonal anti-glucagon receptor ST-18 (anti-GR) or monoclonal anti-phosphoserine (anti-PS) antibodies. Arrows on the right
indicate the mobility of immunodetected glucagon receptor (GR, 62-kDa) and the immunoprecipitating IgG heavy chain (Hc). (C) LPS fraction
was isolated 15 min after glucagon administration, and immediately subfractionated on linear Nycodenz density gradients (left panels), or incubated
with ATP and an ATP-regenerating system at 37 C for 15 min (right panels). Galactosyltransferase (circles) and acid phosphatase (squares) activities
were determined and results expressed as a percentage of total enzymatic activity recovered. Gsa protein content was evaluated for each subfraction
by immunoblotting with the anti-Gsa polyclonal antibody. Thirty ll of each subfraction was loaded onto each lane. Arrows on the right indicate the
mobility of immunodetected Gsa (47- and 45-kDa). Components appearing at densities 1.11–1.145 g/ml (indicated to the bottom of each blot as
‘‘lysosomes’’) were scored as truly lysosomal.
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3.1. Glucagon-induced internalization of serine-phosphorylated
glucagon receptor and Gsa in rat liver
The eﬀect of glucagon administration on the kinetics and ex-
tent of glucagon receptor internalization was studied for
changes in the receptor content as evaluated by Western-blot-
ting (Fig. 1A, upper blot). A time-dependent translocation of
glucagon receptor was observed from the plasma membrane
to endosomes at 5–45 min after glucagon injection (Fig. 1A).
The level of endosomal glucagon receptor was maximum at
15 min and returned to control values by 60 min. We then eval-
uated subcellular fractions prepared from glucagon-injected
rats for their content of Gsa protein and adenylate cyclase
(Fig. 1A, middle and bottom blots, respectively). In control
rats, immunoreactive Gsa (detected as a doublet of 47- and
45-kDa) and adenylate cyclase (detected as a single 170-kDa
protein) were mainly identiﬁed in plasma membrane fractions,
with a small but detectable immunoreactivity observed in
endosomal fractions, consistent with previous reports [20]. In
vivo injection of native glucagon eﬀected a rapid translocation
of both the 47- and 45-kDa Gsa isoforms with maximal accu-
mulation in hepatic endosomes at 15 min post-injection(Fig. 1A, middle blot). No change in adenylate cyclase protein
distribution was observed (Fig. 1A, bottom blot).
Plasma membrane and endosomal fractions were then
immunoprecipitated with anti-glucagon receptor antibody
ST-18 (Fig. 1B). The immunoprecipitates were analyzed by
Western-blotting with the anti-glucagon receptor antibody or
antibodies directed against phosphoserine residues. A rapid
endocytosis of glucagon receptor was still observed (anti-GR
blot) with kinetics comparable to that observed in Fig. 1A.
Phosphoserine immunoreactivity was detected in glucagon
receptor immunoprecipitates from PM (strong immunoreactiv-
ity) and EN (low immunoreactivity) fractions isolated both
from control and glucagon-treated rats (anti-PS blot). No
immunoreactivity was observed with the anti-phosphothreo-
nine or anti-phosphotyrosine antibodies (results not shown).
Transfer of the Gsa protein from the endosomal to the lyso-
somal compartment was next examined by Nycodenz density
gradient analysis of the LPS fractions prepared from gluca-
gon-injected rats (Fig. 1C). When LPS fractions were incu-
bated at 4 C, most of the Gsa protein appeared in a single
broad region of density 1.09–1.115 g/ml (blot on the left),
which coincided mainly with the Golgi marker galactosyl-
transferase (panel on the left). When the LPS fraction was
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the endosomal and lysosomal (1.115–1.13 g/ml) density regions
of the gradient (blot and panel on the right).
3.2. Subcellular distribution of b-arrestins upon glucagon
receptor endocytosis
The b-arrestins control a diverse array of functions in the
regulation of G-protein-coupled receptor (GPCR) signalling
and facilitation of GPCR endocytosis. Consequently, we at-
tempted to evaluate the contribution of b-arrestins to glucagon
receptor endocytosis by assessing hepatic fractions for their
content of b-arrestins 1 and 2 using immunoblot analysis
(Fig. 2). Established protocols were followed to isolate rat liver
homogenate (Hm), nuclear (N), large-granule (ML), micro-
somal (P) and cytosolic (S) fractions. Equal amounts of pro-
tein from these fractions were evaluated for their b-arrestin
content using polyclonal antibodies to b-arrestins 1 and 2
(Fig. 2A). Immunoblot analysis of the Hm revealed a strong
immunoreactivity for b-arrestin 1 (50-kDa) whereas b-arrestin
2 (45-kDa) was only detected at a low level. The S and P frac-
tions contained the highest concentration of b-arrestins 1 and
2, suggesting a dual soluble and membrane-associated location
of b-arrestins in rat liver in vivo. Organelles expected to sedi-
ment in the P fraction, i.e. plasma membrane (PM) and endo-
somes (EN), were partially puriﬁed and evaluated for their
content of b-arrestins (Fig. 2A). The EN fraction showed little
immunoreactivity, while the PM fraction revealed a concentra-
tion of b-arrestins equivalent to that in the P and S fractions.B
A
Fig. 2. Assessment of b-arrestin 1 and 2 by immunoblot analysis of subcell
lysosomal (ML), microsomal (P), cytosolic (S), plasma membrane (PM) and e
evaluated by immunoblotting for their content of b-arrestin 1 and 2 using pol
each lane. Molecular mass markers are indicated to the left. Arrows on the rig
2 (45-kDa). (B) Microsomal (P), cytosolic (S), plasma membrane (PM) and
in vivo administration of native glucagon and evaluated by Western-blotting
b-arrestin 1. Ninety lg (P and S fractions) or ﬁfty lg (PM and EN fractions
immunodetected b-arrestin 1 (50-kDa) and 2 (45-kDa).Neither redistribution of b-arrestins 1 and 2 between the solu-
ble (S fraction) and membrane-associated (P fraction) pools
nor their co-translocation from PM to EN fractions upon glu-
cagon receptor endocytosis was observed, even at early times
after glucagon administration (Fig. 2B).
3.3. Endocytosis and metabolic fate of des-His1-[Glu9]
glucagon amide in rat liver
It has previously been shown that a human glucagon hor-
mone analog, des-His1-[Glu9]glucagon, acts as a glucagon
antagonist [21,22]. However, no study has been directed to-
wards the receptor-mediated endocytic process for this mole-
cule, and its subsequent endosomal degradation remains
unknown. Following administration of a single receptor satu-
rating dose of des-His1-[Glu9]glucagon amide, hepatic PM and
EN fractions were isolated and evaluated for their content of
glucagon receptor by immunoblotting (Fig. 3A, upper blots).
A time-dependent increase in glucagon receptor content was
observed in EN fractions at 5–30 min which was less marked
than that observed following administration of native gluca-
gon (see Fig. 1A). In addition, des-His1-[Glu9]glucagon amide
did not cause a major translocation of the 45- and 47-kDa
isoforms of Gsa to endosomes, although a slight increase
was observed at 30 min post-injection (Fig. 3A, lower blots).
By HPLC analysis, incubation of the ENs fraction with in-
tact glucagon and des-His1-[Glu9]glucagon amide at pH 4
resulted in a rapid generation of degradation products with
40% proteolysis of both peptides within 1 h (Fig. 3B andular fractions isolated from rat liver. (A) Nuclear (N), mitochondrial-
ndosomal (EN) fractions, as well as the isotonic homogenate (Hm) were
yclonal antibody to rat b-arrestin 1. Ninety lg of protein was applied to
ht indicate the mobility of immunodetected b-arrestin 1 (50-kDa) and
endosomal (EN) fractions were isolated at the indicated times after the
for their content of b-arrestin 1 and 2 using polyclonal antibody to rat
) of protein was applied to each lane. Arrows indicate the mobility of
C D
A B
Fig. 3. Internalization and endosomal degradation of des-His1-[Glu9]glucagon in rat liver. (A) Plasma membrane and endosomes were isolated at the
indicated times after the in vivo administration of native des-His1-[Glu9]glucagon and evaluated by Western-blotting for their content of glucagon
receptor (anti-GR) and Gsa (anti-Gsa). Fifty lg of protein was applied to each lane. Arrows on the right indicate the mobility of immunodetected
glucagon receptor (62-kDa) and Gsa (47- and 45-kDa). (B) ENs was incubated with native glucagon or des-His1-[Glu9]glucagon at 37 C for
45 min in 55 mM citrate-phosphate buﬀer, pH 4, or 3 h in 55 mM citrate-phosphate buﬀer, pH 7. At the end of the incubation, the samples were
analyzed by RP-HPLC. Representative absorbance proﬁles at 214 nm were presented. Arrows indicate the elution time of intact peptides. (C) The
rate of hydrolysis of native glucagon peptides was determined by following the disappearance of the peak area corresponding to the parent peptide
(see (B)). The results are expressed as the amount of degraded peptide (% of control). (D) Competition of native glucagon and des-His1-
[Glu9]glucagon for the degradation of [125I]-glucagon by ENs at acidic pH. ENs was incubated with [125I]-glucagon at 37 C and pH 4 with the
indicated concentrations of unlabeled peptides. The amount of degraded radiolabeled glucagon was determined by precipitation with TCA. The
percentage of [125I]-glucagon degraded in the absence of unlabeled peptide was 46% ±6.4. Results are the means of three separate experiments and are
expressed as a percentage of degradation observed in the absence of added unlabeled peptides.
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whereas des-His1-[Glu9]glucagon amide proteolysis did not
exceed 3% (Fig. 3B and C).
We then used a competition assay to evaluate the ability of
native glucagon peptides to inhibit degradation of [125I]-gluca-
gon at acidic pH using the ENs fraction (Fig. 3D). In agree-
ment with previous reports [7], native glucagon was found to
inhibit endosomal proteolysis of iodinated glucagon in a
dose-dependent manner with an IC50 of 106 M comparable
to that observed for native des-His1-[Glu9]glucagon amide.
3.4. Ability of [I4]-glucagon to induce endocytosis of the
glucagon receptor and to activate adenylate cyclase
in rat liver in vivo
Iodoglucagon has been shown to be more potent than gluca-
gon in its ability to bind to the glucagon receptor and to stim-
ulate adenylate cyclase activity in liver membranes in vitro
[9,23]. We therefore examined the ability of [I4]-glucagon to in-
duce internalization of the glucagon receptor and Gsa and to
activate adenylate cyclase in vivo. As native glucagon, [I4]-glu-
cagon underwent endocytosis as judged on the sequential asso-
ciation of injected ligand with the PM and EN fractions
(Fig. 4A). Likewise, it induced a time-dependent and -revers-
ible translocation of the glucagon receptor and Gsa from the
plasma membrane to endosomes (Fig. 4B). However, relative
to glucagon, the retention of [I4]-glucagon in PM and EN frac-tions as well as the redistribution of the glucagon receptor in-
duced by [I4]-glucagon were both of higher magnitude and of
longer duration, the endosomal level of ligand and receptor
reaching a maximum at only 40 min.
Like glucagon [3], [I4]-glucagon caused a time-dependent in-
crease in basal adenylate cyclase activity in EN fractions
in vivo (Fig. 4C). However, unlike glucagon [3], [I4]-glucagon
also increased adenylate cyclase activity in PM and total par-
ticulate (T) fractions (Fig. 4C). Activation of adenylate cyclase
by [I4]-glucagon in vivo occurred earlier in the PM fraction
than in EN fractions, was generally comparable to that in-
duced by glucagon in vitro in control rats and showed little
further increase upon addition of glucagon. In the ENi frac-
tion, however, activation of adenylate cyclase elicited by [I4]-
glucagon in vivo was several fold higher than that induced
by glucagon in vitro, and both activities were additive. When
assayed in the presence of forskolin, adenylate cyclase activity
was increased markedly by [I4]-glucagon administration in the
ENi fraction but only marginally aﬀected in other fractions.4. Discussion
We have previously shown that upon acute occupancy, he-
patic glucagon receptors are rapidly and speciﬁcally internal-
ized along with their ligand to low density endosomes [3,5].
BA C
Fig. 4. Eﬀects of [I4]-glucagon on glucagon receptor and Gsa internalization and adenylate cyclase activity in rat liver in vivo. (A) Plasma membrane
(PM) and endosomal (EN) fractions were isolated at the indicated time after injection of glucagon (G) and [I4]-glucagon ([I4]-G). The ligand content
of these fractions was measured by radioimmunoassay at four separate dilutions using as standards glucagon and [I4]-glucagon, respectively. The
sensitivity of the assay was about 0.1 ng/ml for glucagon and 0.3 ng/ml for [I4]-iodoglucagon. (B) Plasma membrane and endosomes were isolated at
the indicated times after the in vivo administration of native [I4]-glucagon and evaluated by Western-blotting for their content of glucagon receptor
(anti-GR) and Gsa (anti-Gsa). Fifty lg of protein was applied to each lane. Arrows on the right indicate the mobility of immunodetected glucagon
receptor (62-kDa) and Gsa (47- and 45-kDa). Molecular mass markers are indicated to the left of the upper blot. (C) A total particulate fraction
(T), a plasma membrane fraction (PM) and two endosomal fractions of intermediate (ENi) and high (ENh) density were isolated at the indicated
times after injection of [I4]-glucagon. These fractions were assayed for adenylate cyclase activity in the absence (basal activity) or presence of 3 lM
glucagon or 50 lM forskolin. The results are the means ± S.E.M. of 3–6 determinations on separate sets of fractions.
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translocation of glucagon receptor reached a maximum by 12–
24 min, caused a 20% decrease in glucagon binding at the plas-
ma membrane and underwent reversal within 2 h [3]. However,
direct binding studies performed on subcellular fractions iso-
lated from liver homogenates after administration of glucagon
to rats were vitiated by the content of the endogenous ligand
that extensively occupied the glucagon receptor throughout
its internalization pathway [3]. To verify that the speciﬁc bind-
ing assays were representative of changes in glucagon receptor
number, immunoblotting was performed in the present study
with an antibody directed against the distal end of the intracel-
lular C-terminal tail [10]. A time-dependent increase in gluca-
gon receptor content was clearly observed in hepatic
endosomes at 5–45 min after glucagon injection, conﬁrming
the results obtained from the direct binding assays [3]. Also,
the loss of both glucagon binding [3] and immunoreactive glu-
cagon receptor (this study) from plasma membranes was com-
parable and only partial, conﬁrming that the changes in the
subcellular distribution of the glucagon receptor induced by
its ligand are modest.
Short-term signal desensitization of GPCRs is generally
characterized by a phosphorylation event catalyzed by a spe-
ciﬁc GPCR kinase, cAMP-dependent protein kinase (PKA)or protein kinase C (PKC) (reviewed in [24]). Using [32P]-label-
ing of a chinese hamster ovary (CHO) cell line expressing the
human glucagon receptor, it has previously been shown that
glucagon induced a rapid, time- and concentration-dependent
phosphorylation of its receptor on serine residues [25]. Using
the in vivo rat liver model and an immunological approach,
we have conﬁrmed in the present study that the hepatic gluca-
gon receptor was phosphorylated on serine residues in re-
sponse to glucagon, both at the cell surface (strong
phosphoserine immunoreactivity) and after its internalization
into the endosomal apparatus (low phosphoserine immunore-
activity). Neither forskolin nor phorbol ester increased gluca-
gon-induced glucagon receptor phosphorylation, suggesting
that neither PKA nor PKC catalyze this phosphorylation event
[25]. Other studies have implied that protein kinase D might
regulate G-stimulated adenylate cyclase activity in COS cells
transfected to overexpress glucagon receptors [26]. Thus, the
serine kinase responsible for glucagon receptor phosphoryla-
tion induced by glucagon remains to be deﬁned.
A strong correlation between the number of potential phos-
phorylation sites, glucagon receptor phosphorylation and
glucagon receptor internalization has previously been demon-
strated [4,25], implying a role for phosphorylation in the pro-
cess of agonist-induced glucagon receptor internalization.
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mutant glucagon receptor containing seven serine-to-alanine
mutations in the cytoplasmic C-terminal tail [4] display re-
duced internalization capacities and phosphorylation rates.
Our in vivo results support the idea that phosphorylation
may regulate the endocytic process for the glucagon receptor.
Here we also provide evidence that the peptide antagonist des-
His1-[Glu9]glucagon induced a detectable internalization of the
glucagon receptor albeit less pronounced compared to that in-
duced by wild-type glucagon. Consequently, speciﬁc signalling
of the glucagon receptor may be dispensable for glucagon
receptor phosphorylation and endocytosis.
Termination of GPCR-mediated signalling is regulated by
kinase activity, leading to phosphorylation of the receptor
and recruitment of intracellular scaﬀolding proteins such as
b-arrestins from the cytosol, thereby excluding the receptor
from further G protein interaction [24]. However, it is thought
that not all GPCRs internalize in a b-arrestin-dependent man-
ner and no study has addressed whether these cellular pro-
cesses are conserved for the glucagon receptor. Previous
assessment of the tissue distribution of b-arrestins in the rat
has shown that they are predominantly localized in neuronal
tissues and the spleen and are expressed at very low levels in
liver [27]. Moreover, b-arrestin-2 appeared to be more abun-
dant than b-arrestin-1 in most of the rat tissues examined
[27]. In the present work, we conﬁrm both b-arrestin-1 and
-2 immunoreactivity within rat liver homogenate but we found
intense immunoreactivity for b-arrestin-1 only, with moderate
levels for b-arrestin-2. We have also shown in this study that
hepatic b-arrestins are associated with the particulate micro-
somal fraction, the soluble cytosolic fraction and highly puri-
ﬁed plasma membranes.
Glucagon treatment had no discernible eﬀect on the subcel-
lular location of b-arrestins as measured by Western-blot.
Although other experiments using in vitro cell system and/or
RNAi are required to conﬁrm our in vivo data, our report that
glucagon does not induce translocation of b-arrestins to the
plasma membrane and/or endosome of rat liver suggests that
b-arrestins may not play a physiological role in regulating
the glucagon receptor in vivo. Despite the fact that the pre-
dominant pathway for GPCR endocytosis is b-arrestin-depen-
dent [24], alternative endocytic mechanisms may account for
the internalization of some GPCRs such as the b2-adrenergic
receptor, m2 muscarinic acetylcholine receptor and angioten-
sin 1A receptor which internalize normally in the presence of
dominant-negative b-arrestin in speciﬁc cells [24]. A similar
regulation which is b-arrestin-independent appears to apply
for the GLP receptors which belong to GPCR family B [1].
Interestingly, recent studies suggest that GLP-2 receptor traf-
ﬁcking and signalling may, in some instances, be regulated
by clathrin-independent pathways [28]. Studies are required
to evaluate the possibility that glucagon receptor may also uti-
lize alternative clathrin-independent internalization pathways
such as lipid-raft-dependent receptor endocytosis.
The agonist-induced shift of G proteins from the plasma
membrane to low-density endocytic vesicles has been observed
in various cellular systems [29]. Subcellular fractionation stud-
ies using sucrose density gradients have shown that isoprotere-
nol stimulates Gs and Gi protein endocytosis in rat adipocytes
[30] and S49 lymphoma cells [31]. Immunoﬂuorescence micros-
copy studies have revealed comparable Gsa internalization in
transfected HEK-293 cells upon isoproterenol stimulation[32]. Our studies extend these observations to glucagon for
which a maximal endosomal association of Gsa was observed
at 5–30 min post-injection. Moreover, using the in situ rat liver
model system for endosome-lysosome fusion, we also showed
an endo-lysosomal transfer of the two Gsa isoforms in re-
sponse to glucagon. To the best of our knowledge, this is the
ﬁrst such demonstration of a lysosomal association of Gsa
upon agonist stimulation.
Several lines of evidence also indicate that adenylate cyclase
is located in the endocytic vesicles of various cells. Adenylate
cyclase activity sensitive to ﬂuoride [33], isoproterenol [30],
cholera toxin [34] and glucagon [3] has been reported in rat
liver endosomal fractions, and adenylate cyclase VI has re-
cently been detected in hepatic endosomes using Western-blot
analysis [20]. Using the same polyclonal antibody directed
against adenylate cyclase V/VI [20], we have conﬁrmed in the
present study that adenylate cyclase is present within hepatic
endosomal fractions. We have also shown that its endosomal
level was minor compared to that found in plasma membrane
fractions and was unchanged after glucagon treatment.
The N-terminally modiﬁed glucagon analog, des-His1-
[Glu9]glucagon, is a glucagon receptor antagonist, which
emphasizes the importance of His1 and Asp9 of glucagon in
activation of glucagon receptor [35]. In rat liver membrane,
des-His1-[Glu9]glucagon demonstrated a binding potency of
41% relative to that of glucagon, with no detectable adenylate
cyclase activation and an inhibition index of 12 [21,22].
Although much is known about the binding aﬃnity and aden-
ylate cyclase activity of des-His1-[Glu9]glucagon, its receptor-
mediated endocytosis and subsequent endosomal degradation
remained undeﬁned. Our present study has revealed for the
ﬁrst time an internalization of the glucagon receptor within
hepatic endosomes when des-His1-[Glu9]glucagon was used
as the ligand instead of wild-type glucagon. However, the
endocytic pathway for des-His1-[Glu9]glucagon diﬀers from
authentic glucagon in three major points: (i) des-His1-
[Glu9]glucagon was less potent than glucagon in its ability to
increase endosomal glucagon receptor and Gsa protein con-
tent; (ii) the maximal endosomal association of both glucagon
and Gsa was observed at a later time (30 min) following des-
His1-[Glu9]glucagon administration as compared to native
glucagon; (iii) in vitro proteolysis of the antagonist and native
glucagon using endosomal lysates were comparable at acidic
pH (pH 4), but a reduced rate of degradation was observed
for des-His1-[Glu9]glucagon (less than 65% of that of gluca-
gon) at neutral pH.
Iodoglucagons containing 1–5 atoms of iodine per molecule
have been reported to be more potent than glucagon in their
ability to stimulate adenylate cyclase activity in vitro and elicit
hyperglycemia in vivo [9,23], the increased potency being cor-
related with the extent of iodination. This property appears to
result from at least three factors: the increased aﬃnity of
iodoglucagons for the glucagon receptor [9,23]; their reduced
degradation by proteases associated with liver membranes
and blood plasma [9]; and their slower disappearance from
the blood following in vivo injection [9]. The present studies
show that, relative to glucagon, the ability of [I4]-glucagon
to induce a translocation of the glucagon receptor from the
plasma membrane to endosomes and to stimulate adenylate
cyclase activity at these subcellular sites in vivo is both of
higher magnitude and of longer duration. These observations
reﬂect the higher and prolonged retention of [I4]-glucagon at
5704 C. Merlen et al. / FEBS Letters 580 (2006) 5697–5704the plasma membrane and in endosomes, which may itself re-
sults from the slower dissociation of this agonist from the glu-
cagon receptor and/or its reduced degradation by hepatic
proteases.
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